• Filippo Migliorini, Giorgia Colarossi, Jörg Eschweiler, Francesco Oliva, Arne Driessen, and Nicola Maffulli.
• Department of Orthopaedic and Trauma Surgery, University Clinic Aachen, RWTH Aachen University Clinic, Aachen 52074, Germany.
• Br. Med. Bull. 2022 Sep 22; 143 (1): 46-56.

IntroductionCorticosteroid-induced osteoporosis (CIO) is the most common type of secondary osteoporosis, leading to fractures, and increased morbidity and mortality.Source Of DataPubmed, EMBASE, Scopus and Google Scholar databases.Areas Of AgreementProlonged glucocorticoids administration leads to secondary osteoporosis.Areas Of ControversyThe optimal management for CIO is controversial.Growing PointsThe present study compared bone mineral density, fractures and adverse events in patients undergoing treatment with risedronate, alendronate, zoledronate, denosumab or etidronate for CIO.Areas Timely For Developing ResearchFor selected patients with CIO, alendronate performed better overall. These results must be interpreted within the limitations of the present study.Level Of EvidenceI, Bayesian network meta-analysis of randomized clinical trials.© The Author(s) 2022. Published by Oxford University Press.

30 keywords...

hide…